AF
SYRS

Aviso Financial’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Aviso Financial’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-21
Closed -$108 – 383
2024
Q2 		$108 Buy
+21
New +$110 ﹤0.01% 343

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Aviso Financial's SYRS Position: Q3 2024 in Review

Aviso Financial sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2024, closing a stake of 21 shares — an estimated $108 sold.

Aviso Financial first reported a position in SYRS in Q2 2024 and held it in 1 quarter. The position peaked at $108 in Q2 2024. 65 funds tracked by Wall St. Rank hold SYRS as of Q3 2024.

  • Aviso Financial reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Aviso Financial sold 21 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2024, an estimated $108.
  • Aviso Financial first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2024 and held it in 1 quarter.
  • Aviso Financial's Syros Pharmaceuticals, Inc. Common Stock position peaked at $108 in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2024.

Based on Aviso Financial's 13F filing for Q3 2024, filed 13 Nov 2024.